Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNFR1 siRNA
- Development stage
- Preclinical
- Lead developer
- Okayama University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
TNFR1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Tumor Necrosis Factor Receptor 1 (TNFR1). In glioblastoma (GBM), TNFR1 signaling is implicated in tumor maintenance, inflammation, and therapeutic resistance. Research conducted at Okayama University has demonstrated that knockdown of TNFR1 using siRNA sensitizes glioblastoma cells to regulated cell death pathways and reduces tumor cell proliferation. Clinical analysis suggests that high TNFR1 expression is a negative prognostic factor in GBM patients, positioning TNFR1 as a potential therapeutic target to overcome resistance to cell death in this aggressive brain tumor.
- Other names
- TNFR1 knockdownTNFR-1 knockdownTNFR 1 knockdownTNFR1-targeting siRNATNFR-1-targeting siRNATNFR 1-targeting siRNAsiRNA-TNFR1siRNA-TNFR-1siRNA-TNFR 1
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)
Beyond the preview
Go deeper on TNFR1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNFR1 siRNA.